Scholarlink

Purpose <p>To evaluate the impact on survival outcomes of adding concurrent immunotherapy to radiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma following neoadjuvant chemoimmunotherapy.</p> Materials and methods <p>We included patients with stage II–IVA ESCC treated between January 2013 and May 2024. Survival was compared between the radiotherapy without concurrent immunotherapy and radiotherapy with concurrent immunotherapy groups.</p> Results <p>Of the 91 enrolled patients, 35 received radiotherapy without concurrent immunotherapy and 56 received radiotherapy with concurrent immunotherapy. Median overall survival was worse in the radiotherapy without concurrent immunotherapy group compared to the radiotherapy with concurrent immunotherapy group (18 vs. 41 months; hazard ratio = 0.39, 95% confidence interval: 0.18–0.82; <i>P</i> = 0.013). In contrast, no differences were observed in median disease-free survival, locoregional recurrence-free survival, or distant metastasis-free survival between the two groups. Grade ≥ 3 leukopenia and neutropenia occurred more frequently in the concurrent immunotherapy group.</p> Conclusion <p>In this real-world cohort, concurrent immunotherapy was associated with improved overall survival in patients with unresectable locally advanced esophageal squamous cell carcinoma who received prior neoadjuvant chemoimmunotherapy. These findings are hypothesis-generating and highlight the need for prospective randomized trials to validate the optimal integration of immunotherapy in this multimodal treatment sequence.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Radiotherapy with versus without concurrent immunotherapy following neoadjuvant chemoimmunotherapy in unresectable locally advanced esophageal squamous cell carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月16日

查看全文
  • Run-Zhi Wang,
  • Cheng-Xian Ma,
  • Huan-Wei Liang,
  • Wei Huang,
  • Xin-Bin Pan

摘要

Purpose

To evaluate the impact on survival outcomes of adding concurrent immunotherapy to radiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma following neoadjuvant chemoimmunotherapy.

Materials and methods

We included patients with stage II–IVA ESCC treated between January 2013 and May 2024. Survival was compared between the radiotherapy without concurrent immunotherapy and radiotherapy with concurrent immunotherapy groups.

Results

Of the 91 enrolled patients, 35 received radiotherapy without concurrent immunotherapy and 56 received radiotherapy with concurrent immunotherapy. Median overall survival was worse in the radiotherapy without concurrent immunotherapy group compared to the radiotherapy with concurrent immunotherapy group (18 vs. 41 months; hazard ratio = 0.39, 95% confidence interval: 0.18–0.82; P = 0.013). In contrast, no differences were observed in median disease-free survival, locoregional recurrence-free survival, or distant metastasis-free survival between the two groups. Grade ≥ 3 leukopenia and neutropenia occurred more frequently in the concurrent immunotherapy group.

Conclusion

In this real-world cohort, concurrent immunotherapy was associated with improved overall survival in patients with unresectable locally advanced esophageal squamous cell carcinoma who received prior neoadjuvant chemoimmunotherapy. These findings are hypothesis-generating and highlight the need for prospective randomized trials to validate the optimal integration of immunotherapy in this multimodal treatment sequence.